Would the Choose France summit, intended to promote foreign investments on the national territory, aim to expand with Franco-French “off programming”? While the seventh edition of this annual high mass, which is being held on Monday May 13 at the Palace of Versailles, promises a record harvest of announcements, the French laboratory Sanofi has just unveiled, on the sidelines of the event, an investment of 1 .1 billion euros, in order to strengthen its drug manufacturing capacities in France.
“We chose France a long time ago, and we continue to do so. This investment will contribute to our health sovereignty “, confides Audrey Derveloy, president of Sanofi France. The French flagship is thus doubling down on investments in health already disclosed within the framework of Choose France. The Elysée had in fact confirmed, on Sunday May 12, investments from the American laboratory Pfizer (500 million euros), the Anglo-Swedish AstraZeneca (365 million euros), the British GSK (140 million euros ) and the Swiss Novartis (28 million euros), for a total amount of just over 1 billion euros.
Around 91% of the envelope presented Monday by Sanofi, or 1 billion euros, will be devoted to the creation of a new factory on the group’s century-old site located in Vitry-sur-Seine (Val-de-Marne), where the laboratory already produces several of its drugs, including its treatment against hypercholesterolemia, Praluent, the anticancer Sarclisa against multiple myeloma (a cancer of the bone marrow) or even Kevzara, used in patients with rheumatoid arthritis .
A portfolio of twelve molecules with high potential
The future building will, once built, double the production capacity of monoclonal antibodies at the Vitry-sur-Seine site, with the aim of housing some of the group’s next drugs currently under construction. development, for example “ in chronic bronchitis, asthma, multiple sclerosis or type 1 diabetes »details the company.
In December 2023, Sanofi highlighted a portfolio of twelve high-potential molecules, capable, once marketed, of each generating revenues of more than 1 billion euros. “We built this industrial project by looking at this portfolio, with the ambition of creating a continuum between the development of these drugs, which, for a large part of these molecules, is carried out partly in France, and their production”, explains Audrey Derveloy. Like the Sarclisa treatment, developed and then manufactured in Vitry-sur-Seine.
You have 48.53% of this article left to read. The rest is reserved for subscribers.